[go: up one dir, main page]

WO2004065569A3 - Multi-functional antibodies - Google Patents

Multi-functional antibodies Download PDF

Info

Publication number
WO2004065569A3
WO2004065569A3 PCT/US2004/001808 US2004001808W WO2004065569A3 WO 2004065569 A3 WO2004065569 A3 WO 2004065569A3 US 2004001808 W US2004001808 W US 2004001808W WO 2004065569 A3 WO2004065569 A3 WO 2004065569A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
functional antibodies
present
antigen recognition
reactive site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/001808
Other languages
French (fr)
Other versions
WO2004065569A2 (en
Inventor
Claude Meares
Todd Corneillie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/350,555 external-priority patent/US7528235B2/en
Priority claimed from US10/625,047 external-priority patent/US7820787B2/en
Priority claimed from US10/631,258 external-priority patent/US20050026263A1/en
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2004065569A2 publication Critical patent/WO2004065569A2/en
Publication of WO2004065569A3 publication Critical patent/WO2004065569A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides antibodies comprising an antigen recognition domain that specifically binds to a metal chelate: mutant antibodies comprising a reactive site not present in the wild-type of the antibody, wherein the reactive site is in a position proximate to or within the antigen recognition domain; and methods of using such antibodies to diagnose and treat disease.
PCT/US2004/001808 2003-01-23 2004-01-23 Multi-functional antibodies Ceased WO2004065569A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/350,555 2003-01-23
US10/350,555 US7528235B2 (en) 2003-01-23 2003-01-23 Multi-functional antibodies
US10/625,047 2003-07-22
US10/625,047 US7820787B2 (en) 2003-01-23 2003-07-22 Multi-functional antibodies
US10/631,258 US20050026263A1 (en) 2003-07-31 2003-07-31 Multi-functional antibodies
US10/631,258 2003-07-31

Publications (2)

Publication Number Publication Date
WO2004065569A2 WO2004065569A2 (en) 2004-08-05
WO2004065569A3 true WO2004065569A3 (en) 2005-03-24

Family

ID=32776952

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/001808 Ceased WO2004065569A2 (en) 2003-01-23 2004-01-23 Multi-functional antibodies

Country Status (1)

Country Link
WO (1) WO2004065569A2 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US9765153B2 (en) 2012-07-04 2017-09-19 Hoffmann-La Roche Inc. Anti-biotin antibodies and methods of use
US9925272B2 (en) 2012-07-04 2018-03-27 Hoffmann-La Roche Inc. Anti-theophylline antibodies and methods of use
US10407511B2 (en) 2014-01-03 2019-09-10 Hoffmann-La Roche Inc. Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
US10517945B2 (en) 2012-07-04 2019-12-31 Hoffman-La Roche Inc. Covalently linked antigen-antibody conjugates
US10519249B2 (en) 2014-01-03 2019-12-31 Hoffmann-La Roche Inc. Covalently linked polypeptide toxin-antibody conjugates
US11673968B2 (en) 2014-06-26 2023-06-13 Hoffmann-La Roche Inc. Anti-BRDU antibodies and methods of use

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063209A1 (en) * 2004-08-20 2006-03-23 The Regents Of The University Of California Engineered antibody fragment that irreversibly binds an antigen
PL1976877T5 (en) 2005-11-30 2017-09-29 Abbvie Inc Monoclonal antibodies against amyloid beta protein and uses thereof
US20090093618A1 (en) * 2006-05-05 2009-04-09 The Regents Of The University Of Californa Streptavidin-biotin-link antibody-hapten system
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
ES2548102T3 (en) * 2007-06-12 2015-10-13 Ac Immune S.A. Anti beta amyloid monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
MX373097B (en) 2014-01-03 2020-04-27 Hoffmann La Roche Bispecific anti-hapten/anti-blood-brain barrier receptor antibodies, their complexes, and their use as carriers across the blood-brain barrier.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958374A (en) * 1994-03-28 1999-09-28 The Regents Of The University Of California Method for preparing radionuclide-labeled chelating agent-ligand complexes
WO2001022922A2 (en) * 1999-09-27 2001-04-05 The Regents Of The University Of California Engineering antibodies that bind irreversibly
US20030124057A1 (en) * 2001-11-28 2003-07-03 Immunomedics, Inc. Anti-DOTA antibody

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958374A (en) * 1994-03-28 1999-09-28 The Regents Of The University Of California Method for preparing radionuclide-labeled chelating agent-ligand complexes
WO2001022922A2 (en) * 1999-09-27 2001-04-05 The Regents Of The University Of California Engineering antibodies that bind irreversibly
US20030124057A1 (en) * 2001-11-28 2003-07-03 Immunomedics, Inc. Anti-DOTA antibody

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHMURA ET AL.: "Antibodies with infinite affinity", PNAS, vol. 98, no. 15, 17 July 2001 (2001-07-17), pages 8480 - 8484, XP002984342 *
CORNEILLIE ET AL.: "Converting weak binders into infinite binders", BIOCONJUGATE CHEM., vol. 15, 2004, pages 1389 - 1391, XP002984341 *
CORNEILLIE ET AL.: "Crystal structures of two complexes of the rare-earth-DOTA-binding antibody 2D12.5: ligand generality from a chiral system", J. AM. CHEM. SOC., vol. 125, 2003, pages 15039 - 15048, XP002984343 *
CORNEILLIE ET AL.: "Irreversible engineering of the multielement-binding antibody 2D12.5 and its complementary ligands", BIOCONJUGATE CHEM., vol. 15, 2004, pages 1392 - 1402, XP002984344 *
GOODWIN ET AL.: "Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouese adenocarcinoma: a model for 90Y radioimmunotherapy", CANCER RES., vol. 54, no. 22, 15 November 1994 (1994-11-15), pages 5937 - 5946, XP000199874 *
LUBIC ET AL.: "Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma", J. NUCL. MED., vol. 42, no. 4, April 2001 (2001-04-01), pages 670 - 678, XP002984340 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9925272B2 (en) 2012-07-04 2018-03-27 Hoffmann-La Roche Inc. Anti-theophylline antibodies and methods of use
US9765153B2 (en) 2012-07-04 2017-09-19 Hoffmann-La Roche Inc. Anti-biotin antibodies and methods of use
US10517945B2 (en) 2012-07-04 2019-12-31 Hoffman-La Roche Inc. Covalently linked antigen-antibody conjugates
US12023378B2 (en) 2012-07-04 2024-07-02 Hoffmann-La Roche Inc. Covalently linked antigen-antibody conjugates
US10407511B2 (en) 2014-01-03 2019-09-10 Hoffmann-La Roche Inc. Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
US10519249B2 (en) 2014-01-03 2019-12-31 Hoffmann-La Roche Inc. Covalently linked polypeptide toxin-antibody conjugates
US11673968B2 (en) 2014-06-26 2023-06-13 Hoffmann-La Roche Inc. Anti-BRDU antibodies and methods of use

Also Published As

Publication number Publication date
WO2004065569A2 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
WO2004065569A3 (en) Multi-functional antibodies
WO2003074679A3 (en) Antibody optimization
ZA200702879B (en) Single domain antibodies against TNFR1 and methods of use therefor
WO2007022520A3 (en) Antibody-mediated enhancement of immune response
NZ599683A (en) Anti-ilt7 antibody
WO2006066078A3 (en) Fcϝriib-specific antibodies and methods of use thereof
WO2002016401A3 (en) Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof
WO2002075274A3 (en) Method and kit for following neurodegenerative diseases
WO2007131242A3 (en) Streptavidin-biotin-link antibody-hapten system
EP1139101A3 (en) Immunoassay for c-reactive protein
WO2003060080A3 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
WO2004022717A3 (en) Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen
WO2004001381A8 (en) Novel raag10 cell surface target and a family of antibodies recognizing that target
NZ607711A (en) Antibodies directed to her-3 and uses thereof
WO2005047860A3 (en) Antibodies to alpha-synuclein
WO2005026209A3 (en) Monoclonal antibodies against hmgb1
TR200202799T3 (en) Humanized antibodies that sequence the AB peptide
AU2001268855A1 (en) Single-domain antigen-binding antibody fragments derived from llama antibodies
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
WO2005010048A3 (en) Rg1 antibodies and uses thereof
WO2003048302A3 (en) Identifying anti-tumor targets or agents by lipid raft immunization and proteomics
WO2003032814A3 (en) Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof
CA2348026A1 (en) Antibodies against semp1, methods for their production and uses thereof
AU2002327704A1 (en) Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
WO2003087340A3 (en) Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase